Value of an Integrated Home Dialysis Model in the United Kingdom: A Cost-Effectiveness Analysis

被引:5
|
作者
Erbe, Amanda W. [1 ,4 ]
Kendzia, Dana [2 ]
Busink, Ellen [2 ]
Carroll, Suzanne [3 ]
Aas, Eline [1 ]
机构
[1] Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, Norway
[2] Fresenius Med Care, Market Access & Hlth Econ, Bad Homburg, Germany
[3] Fresenius Med Care UK Ltd, Hlth Econ, Market Access & Prod Management, Huthwaite, England
[4] Univ Oslo, Dept Hlth Management & Hlth Econ, POB 1089 Blindern, Oslo 0317, Norway
关键词
economic evaluation; home hemodialysis; home -to -home transition; patient pathway management; peritoneal; dialysis; renal replacement therapy; QUALITY-OF-LIFE; PERITONEAL-DIALYSIS; HEMODIALYSIS; DISEASE; UTILITY; RISK;
D O I
10.1016/j.jval.2023.02.009
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: This study aimed to determine the lifetime cost-effectiveness of increasing home hemodialysis as a treatment option for patients experiencing peritoneal dialysis technique failure compared with the current standard of care.Methods: A Markov model was developed to assess the lifetime costs, quality-adjusted life-years, and cost-effectiveness of increasing the usage an integrated home dialysis model compared with the current patient pathways in the United Kingdom. A secondary analysis was conducted including only the cost difference in treatments, minimizing the impact of the high cost of dialysis during life-years gained. Sensitivity and scenario analyses were performed, including analyses from a societal rather than a National Health Service perspective.Results: The base-case probabilistic analysis was associated with incremental costs of & POUND;3413 and a quality-adjusted life-year of 0.09, resulting in an incremental cost-effectiveness ratio of & POUND;36341. The secondary analysis found the integrated home dialysis model to be dominant. Conclusions on cost-effectiveness did not change under the societal perspective in eitherConclusions: The base-case analysis found that an integrated home dialysis model compared with current patient pathways is likely not cost-effective. These results were primarily driven by the high baseline costs of dialysis during life-years gained by patients receiving home hemodialysis. When excluding baseline dialysis-related treatment costs, the integrated home dialysis model was dominant. New strategies in kidney care patient pathway management should be explored because, under the assumption that dialysis should be funded, the results provide cost-effectiveness evidence for an integrated home dialysis model.
引用
收藏
页码:984 / 994
页数:11
相关论文
共 50 条
  • [31] Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis
    Gray, Ewan
    Donten, Anna
    Karssemeijer, Nico
    van Gils, Carla
    Evans, D. Gareth
    Astley, Sue
    Payne, Katherine
    VALUE IN HEALTH, 2017, 20 (08) : 1100 - 1109
  • [32] COST-EFFECTIVENESS ANALYSIS OF DIALYSIS THERAPY PROGRAM IN CHINA
    Liu, Jing
    Zeng, Xiaoxi
    Ma, Liang
    Fu, Ping
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [33] The cost-effectiveness of integrated home care and discharge practice for home care patients
    Hammar, Teija
    Rissanen, Pekka
    Perala, Marja-Leena
    HEALTH POLICY, 2009, 92 (01) : 10 - 20
  • [34] Cost-effectiveness analysis in the United States - Reply
    Pearson, SD
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (23): : 2722 - 2723
  • [35] Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
    Gabriel Tremblay
    Mike Dolph
    Sachin Patel
    Patricia Brandt
    Anna Forsythe
    Cost Effectiveness and Resource Allocation, 16
  • [36] Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom
    Jorgensen, Tine Rikke
    Stein, Dan J.
    Despiegel, Nicolas
    Drost, Pieter B.
    Hernels, Michiel E. H.
    Baldwin, David S.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (10) : 1752 - 1758
  • [37] Probabilistic cost-effectiveness analysis of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom
    Hemels, ME
    Toumi, I
    Wade, AG
    VALUE IN HEALTH, 2004, 7 (06) : 779 - 779
  • [38] Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
    Tremblay, Gabriel
    Dolph, Mike
    Patel, Sachin
    Brandt, Patricia
    Forsythe, Anna
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
  • [39] Improving value measurement in cost-effectiveness analysis
    Ubel, PA
    Nord, E
    Gold, M
    Menzel, P
    Prades, JLP
    Richardson, J
    MEDICAL CARE, 2000, 38 (09) : 892 - 901
  • [40] The cost-effectiveness of home birth
    Anderson, RE
    Anderson, DA
    JOURNAL OF NURSE-MIDWIFERY, 1999, 44 (01): : 30 - 35